Consecutive intrabronchial administration of Wharton’s jelly-derived mesenchymal stromal cells in ECMO-supported pediatric patients with end-stage interstitial lung disease: a safety and feasibility study (CIBA method)
Authors:
Open Access
- 5 April 2025
- journal article
- case report
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 164
Abstract
Patients ineligible for lung transplant with end-stage Interstitial Lung Disease (ILD) on Extra-Corporeal Membrane Oxygenation (ECMO) face an appalling prognosis with limited therapeutic options. Due to the beneficial effect of Mesenchymal Stromal Cells (MSC) on inflammatory, immunological and infectious diseases, cell therapy has been proposed as an option, but administration is hampered by the ECMO. Cryopreserved Wharton-jelly derived MSC (WJ-MSC) were conveniently diluted and directly applied consecutively on each lobule (5,1 ml = 107 cells) at a continuous slow rate infused over one hour via flexible bronchoscopy (Consecutive IntraBronchial Administration method, CIBA method). Intrabronchial administration of MSC to a patient on ECMO was well tolerated by the patient even though it did not reverse the patient's ILD. This manuscript presents preliminary evidence from ongoing clinical trials program on Cell Therapy of Inflammatory, Immune and Infectious Diseases and, to our knowledge, is the first report of intrabronchial administration of MSC in a paediatric ECMO patient with ILD. Even more, MSC administered by this method do not reach the systemic circulation and do get blocked on ECMO membrane. Direct intrabronchial administration of MSC in a patient on ECMO is feasible and safe, and may be a new avenue to be assayed in ECMO patients with inflammatory, immunological and infectious diseases of the lung.Keywords
Funding Information
- Al-Andalus Biopharma SL (Al-Andalus Biopharma SL)
- Agencia Valenciana de Innovación (AVI-GVA COVID-19-068, GVA-COVID19/2021/047)
- Juvenile Diabetes Research Foundation (JDRF 2-SRA-2019-837)
- Instituto de Salud Carlos III (ICI21/00016, DTS19/00175)
- Université Toulouse III - Paul Sabatier (FIS PI21/01642)
- Institute of Health Carlos III (PDC2022-133952-100)
This publication has 57 references indexed in Scilit:
- Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical TrialThe Journal of Pediatrics, 2014
- Study of the stability of packaging and storage conditions of human mesenchymal stem cell for intra-arterial clinical application in patient with critical limb ischemiaEuropean Journal of Pharmaceutics and Biopharmaceutics, 2014
- Intratracheal Administration of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in a Patient with Acute Respiratory Distress SyndromeJournal of Korean Medical Science, 2014
- Adipose Mesenchymal Stromal Cells Isolated From Type 2 Diabetic Patients Display Reduced Fibrinolytic ActivityDiabetes, 2013
- Bone marrow-derived mononuclear cells vs. mesenchymal stromal cells in experimental allergic asthmaRespiratory Physiology & Neurobiology, 2013
- Effects of Intratracheal Mesenchymal Stromal Cell Therapy during Recovery and Resolution after Ventilator-induced Lung InjuryAnesthesiology, 2013
- Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasiaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Mesenchymal stem cells enhance survival and bacterial clearance in murineEscherichia colipneumoniaThorax, 2012
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?The International Journal of Biochemistry & Cell Biology, 2008
- Open lung biopsy in neonatal and paediatric patients referred for extracorporeal membrane oxygenation (ECMO)Thorax, 2004